Click for best price
Multivalent Vaccines Market Size, Share 2022
Market Analysis and Insights: Global Multivalent Vaccines Market
The global Multivalent Vaccines market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Multivalent Vaccines market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Multivalent Vaccines market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Multivalent Vaccines market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Multivalent Vaccines market.
Global Multivalent Vaccines Scope and Market Size
Multivalent Vaccines market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Multivalent Vaccines market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.
For United States market, this report focuses on the Multivalent Vaccines market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.
Segment by Type
Conjugate Vaccines
Inactivated and Subunit Vaccines
Live Attenuated Vaccines
Toxoid Vaccines
Recombinant Vaccines
Segment by Application
Pediatrics
Adults
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
GlaxoSmithKline, plc (U.K.)
Pfizer, Inc (US)
Merck & Co., Inc (US)
Sanofi Pasteur SA (France)
Astellas Pharma Inc. (Japan)
CSL Limited (Australia)
Emergent BioSolutions, Inc (US)
Johnson & Johnson (US)
MedImmune, LLC (US)
Serum Institute of India Pvt. Ltd. (India)
Bavarian Nordic (Denmark)
Mitsubishi Tanabe Pharma Corporation (Japan)
Daiichi Sankyo (Japan)
Protein Sciences Corporation (US)
Panacea Biotec (India)
The information for each competitor/Company Profile includes:
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
The content of the study subjects includes a total of 15 chapters:
Chapter 1, describes Multivalent Vaccines product scope, market overview, market opportunities, market driving force, and market risks.
Chapter 2, profiles the top manufacturers of Multivalent Vaccines, with price, sales, revenue, and global market share of Multivalent Vaccines from 2019 to 2022.
Chapter 3, the Multivalent Vaccines competitive situation, sales, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Multivalent Vaccines breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapters 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, and application, from 2017 to 2028.
Chapters 7, 8, 9, 10, and 11, to break the sales data at the country level, with sales, revenue, and market share for key countries in the world, from 2017 to 2022. and the Multivalent Vaccines market forecast, by regions, type, and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Multivalent Vaccines.
Chapter 13, 14, and 15, to describe Multivalent Vaccines sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Key Indicators Analysed:
- Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2027 & Sales with a thorough analysis of the market?s competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.
- Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2016-2027. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications.
- Market Trends: Market key trends which include Increased Competition and Continuous Innovations.
- Opportunities and Drivers: Identifying the Growing Demands and New Technology
- Porters Five Force Analysis: The report provides with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.
Reasons to Purchase this Report:
- Estimates 2022-2027 2021-2025 Multivalent Vaccines Report on, Status and Forecast, by Players, Types and Applications market development trends with the recent trends and SWOT analysis
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
- Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
- Market value (USD Million) and volume (Units Million) data for each segment and sub-segment
- Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
- Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
- 1-year analyst support, along with the data support in excel format.
Research Methodology:
The research methodology used to estimate and forecast this market begins by capturing the revenues of the key players and their shares in the market. Various secondary sources such as press releases, annual reports, non-profit organizations, industry associations, governmental agencies and customs data, have been used to identify and collect information useful for this extensive commercial study of the market. Calculations based on this led to the overall market size. After arriving at the overall market size, the total market has been split into several segments and subsegments, which have then been verified through primary research by conducting extensive interviews with industry experts such as CEOs, VPs, directors, and executives. The data triangulation and market breakdown procedures have been employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.
| Report Attributes |
Report Details |
| Report Title |
Global and United States Multivalent Vaccines Market Report & Forecast 2022-2028 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2021 |
| Forecast Year |
2029 |
| Number of Pages |
113 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Study Coverage
1.1 Multivalent Vaccines Product Introduction
1.2 Global Multivalent Vaccines Outlook 2017 VS 2022 VS 2028
1.2.1 Global Multivalent Vaccines Sales in US$ Million for the Year 2017-2028
1.2.2 Global Multivalent Vaccines Sales in Volume for the Year 2017-2028
1.3 United States Multivalent Vaccines Outlook 2017 VS 2022 VS 2028
1.3.1 United States Multivalent Vaccines Sales in US$ Million for the Year 2017-2028
1.3.2 United States Multivalent Vaccines Sales in Volume for the Year 2017-2028
1.4 Multivalent Vaccines Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.4.1 The Market Share of United States Multivalent Vaccines in Global, 2017 VS 2022 VS 2028
1.4.2 The Growth Rate of Multivalent Vaccines Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.5 Multivalent Vaccines Market Dynamics
1.5.1 Multivalent Vaccines Industry Trends
1.5.2 Multivalent Vaccines Market Drivers
1.5.3 Multivalent Vaccines Market Challenges
1.5.4 Multivalent Vaccines Market Restraints
1.6 Study Objectives
1.7 Years Considered
2 Market by Type
2.1 Multivalent Vaccines Market Segment by Type
2.1.1 Conjugate Vaccines
2.1.2 Inactivated and Subunit Vaccines
2.1.3 Live Attenuated Vaccines
2.1.4 Toxoid Vaccines
2.1.5 Recombinant Vaccines
2.2 Global Multivalent Vaccines Market Size by Type
2.2.1 Global Multivalent Vaccines Sales in Value, by Type (2017, 2022 & 2028)
2.2.2 Global Multivalent Vaccines Sales in Volume, by Type (2017, 2022 & 2028)
2.2.3 Global Multivalent Vaccines Average Selling Price (ASP) by Type (2017, 2022 & 2028)
2.3 United States Multivalent Vaccines Market Size by Type
2.3.1 United States Multivalent Vaccines Sales in Value, by Type (2017, 2022 & 2028)
2.3.2 United States Multivalent Vaccines Sales in Volume, by Type (2017, 2022 & 2028)
2.3.3 United States Multivalent Vaccines Average Selling Price (ASP) by Type (2017, 2022 & 2028)
3 Market by Application
3.1 Multivalent Vaccines Market Segment by Application
3.1.1 Pediatrics
3.1.2 Adults
3.2 Global Multivalent Vaccines Market Size by Application
3.2.1 Global Multivalent Vaccines Sales in Value, by Application (2017, 2022 & 2028)
3.2.2 Global Multivalent Vaccines Sales in Volume, by Application (2017, 2022 & 2028)
3.3.3 Global Multivalent Vaccines Average Selling Price (ASP) by Application (2017, 2022 & 2028)
3.3 United States Multivalent Vaccines Market Size by Application
3.3.1 United States Multivalent Vaccines Sales in Value, by Application (2017, 2022 & 2028)
3.3.2 United States Multivalent Vaccines Sales in Volume, by Application (2017, 2022 & 2028)
3.3.3 United States Multivalent Vaccines Average Selling Price (ASP) by Application (2017, 2022 & 2028)
4 Global Multivalent Vaccines Competitor Landscape by Company
4.1 Global Multivalent Vaccines Market Size by Company
4.1.1 Top Global Multivalent Vaccines Manufacturers Ranked by Revenue (2021)
4.1.2 Global Multivalent Vaccines Revenue by Manufacturer (2017-2022)
4.1.3 Global Multivalent Vaccines Sales by Manufacturer (2017-2022)
4.1.4 Global Multivalent Vaccines Price by Manufacturer (2017-2022)
4.2 Global Multivalent Vaccines Concentration Ratio (CR)
4.2.1 Multivalent Vaccines Market Concentration Ratio (CR) (2017-2022)
4.2.2 Global Top 5 and Top 10 Largest Manufacturers of Multivalent Vaccines in 2021
4.2.3 Global Multivalent Vaccines Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Multivalent Vaccines Manufacturing Base Distribution, Product Type
4.3.1 Global Multivalent Vaccines Manufacturers, Headquarters and Distribution of Producing Region
4.3.2 Manufacturers Multivalent Vaccines Product Type
4.3.3 Date of International Manufacturers Enter into Multivalent Vaccines Market
4.4 Manufacturers Mergers & Acquisitions, Expansion Plans
4.5 United States Multivalent Vaccines Market Size by Company
4.5.1 Top Multivalent Vaccines Players in United States, Ranked by Revenue (2021)
4.5.2 United States Multivalent Vaccines Revenue by Players (2020, 2021 & 2022)
4.5.3 United States Multivalent Vaccines Sales by Players (2020, 2021 & 2022)
5 Global Multivalent Vaccines Market Size by Region
5.1 Global Multivalent Vaccines Market Size by Region: 2017 VS 2022 VS 2028
5.2 Global Multivalent Vaccines Market Size in Volume by Region (2017-2028)
5.2.1 Global Multivalent Vaccines Sales in Volume by Region: 2017-2022
5.2.2 Global Multivalent Vaccines Sales in Volume Forecast by Region (2023-2028)
5.3 Global Multivalent Vaccines Market Size in Value by Region (2017-2028)
5.3.1 Global Multivalent Vaccines Sales in Value by Region: 2017-2022
5.3.2 Global Multivalent Vaccines Sales in Value by Region: 2023-2028
6 Segment in Region Level & Country Level
6.1 North America
6.1.1 North America Multivalent Vaccines Market Size YoY Growth 2017-2028
6.1.2 North America Multivalent Vaccines Market Facts & Figures by Country (2017, 2022 & 2028)
6.1.3 U.S.
6.1.4 Canada
6.2 Asia-Pacific
6.2.1 Asia-Pacific Multivalent Vaccines Market Size YoY Growth 2017-2028
6.2.2 Asia-Pacific Multivalent Vaccines Market Facts & Figures by Region (2017, 2022 & 2028)
6.2.3 China
6.2.4 Japan
6.2.5 South Korea
6.2.6 India
6.2.7 Australia
6.2.8 Taiwan
6.2.9 Indonesia
6.2.10 Thailand
6.2.11 Malaysia
6.2.12 Philippines
6.3 Europe
6.3.1 Europe Multivalent Vaccines Market Size YoY Growth 2017-2028
6.3.2 Europe Multivalent Vaccines Market Facts & Figures by Country (2017, 2022 & 2028)
6.3.3 Germany
6.3.4 France
6.3.5 U.K.
6.3.6 Italy
6.3.7 Russia
6.4 Latin America
6.4.1 Latin America Multivalent Vaccines Market Size YoY Growth 2017-2028
6.4.2 Latin America Multivalent Vaccines Market Facts & Figures by Country (2017, 2022 & 2028)
6.4.3 Mexico
6.4.4 Brazil
6.4.5 Argentina
6.5 Middle East and Africa
6.5.1 Middle East and Africa Multivalent Vaccines Market Size YoY Growth 2017-2028
6.5.2 Middle East and Africa Multivalent Vaccines Market Facts & Figures by Country (2017, 2022 & 2028)
6.5.3 Turkey
6.5.4 Saudi Arabia
6.5.5 U.A.E
7 Company Profiles
7.1 GlaxoSmithKline, plc (U.K.)
7.1.1 GlaxoSmithKline, plc (U.K.) Corporation Information
7.1.2 GlaxoSmithKline, plc (U.K.) Description and Business Overview
7.1.3 GlaxoSmithKline, plc (U.K.) Multivalent Vaccines Sales, Revenue and Gross Margin (2017-2022)
7.1.4 GlaxoSmithKline, plc (U.K.) Multivalent Vaccines Products Offered
7.1.5 GlaxoSmithKline, plc (U.K.) Recent Development
7.2 Pfizer, Inc (US)
7.2.1 Pfizer, Inc (US) Corporation Information
7.2.2 Pfizer, Inc (US) Description and Business Overview
7.2.3 Pfizer, Inc (US) Multivalent Vaccines Sales, Revenue and Gross Margin (2017-2022)
7.2.4 Pfizer, Inc (US) Multivalent Vaccines Products Offered
7.2.5 Pfizer, Inc (US) Recent Development
7.3 Merck & Co., Inc (US)
7.3.1 Merck & Co., Inc (US) Corporation Information
7.3.2 Merck & Co., Inc (US) Description and Business Overview
7.3.3 Merck & Co., Inc (US) Multivalent Vaccines Sales, Revenue and Gross Margin (2017-2022)
7.3.4 Merck & Co., Inc (US) Multivalent Vaccines Products Offered
7.3.5 Merck & Co., Inc (US) Recent Development
7.4 Sanofi Pasteur SA (France)
7.4.1 Sanofi Pasteur SA (France) Corporation Information
7.4.2 Sanofi Pasteur SA (France) Description and Business Overview
7.4.3 Sanofi Pasteur SA (France) Multivalent Vaccines Sales, Revenue and Gross Margin (2017-2022)
7.4.4 Sanofi Pasteur SA (France) Multivalent Vaccines Products Offered
7.4.5 Sanofi Pasteur SA (France) Recent Development
7.5 Astellas Pharma Inc. (Japan)
7.5.1 Astellas Pharma Inc. (Japan) Corporation Information
7.5.2 Astellas Pharma Inc. (Japan) Description and Business Overview
7.5.3 Astellas Pharma Inc. (Japan) Multivalent Vaccines Sales, Revenue and Gross Margin (2017-2022)
7.5.4 Astellas Pharma Inc. (Japan) Multivalent Vaccines Products Offered
7.5.5 Astellas Pharma Inc. (Japan) Recent Development
7.6 CSL Limited (Australia)
7.6.1 CSL Limited (Australia) Corporation Information
7.6.2 CSL Limited (Australia) Description and Business Overview
7.6.3 CSL Limited (Australia) Multivalent Vaccines Sales, Revenue and Gross Margin (2017-2022)
7.6.4 CSL Limited (Australia) Multivalent Vaccines Products Offered
7.6.5 CSL Limited (Australia) Recent Development
7.7 Emergent BioSolutions, Inc (US)
7.7.1 Emergent BioSolutions, Inc (US) Corporation Information
7.7.2 Emergent BioSolutions, Inc (US) Description and Business Overview
7.7.3 Emergent BioSolutions, Inc (US) Multivalent Vaccines Sales, Revenue and Gross Margin (2017-2022)
7.7.4 Emergent BioSolutions, Inc (US) Multivalent Vaccines Products Offered
7.7.5 Emergent BioSolutions, Inc (US) Recent Development
7.8 Johnson & Johnson (US)
7.8.1 Johnson & Johnson (US) Corporation Information
7.8.2 Johnson & Johnson (US) Description and Business Overview
7.8.3 Johnson & Johnson (US) Multivalent Vaccines Sales, Revenue and Gross Margin (2017-2022)
7.8.4 Johnson & Johnson (US) Multivalent Vaccines Products Offered
7.8.5 Johnson & Johnson (US) Recent Development
7.9 MedImmune, LLC (US)
7.9.1 MedImmune, LLC (US) Corporation Information
7.9.2 MedImmune, LLC (US) Description and Business Overview
7.9.3 MedImmune, LLC (US) Multivalent Vaccines Sales, Revenue and Gross Margin (2017-2022)
7.9.4 MedImmune, LLC (US) Multivalent Vaccines Products Offered
7.9.5 MedImmune, LLC (US) Recent Development
7.10 Serum Institute of India Pvt. Ltd. (India)
7.10.1 Serum Institute of India Pvt. Ltd. (India) Corporation Information
7.10.2 Serum Institute of India Pvt. Ltd. (India) Description and Business Overview
7.10.3 Serum Institute of India Pvt. Ltd. (India) Multivalent Vaccines Sales, Revenue and Gross Margin (2017-2022)
7.10.4 Serum Institute of India Pvt. Ltd. (India) Multivalent Vaccines Products Offered
7.10.5 Serum Institute of India Pvt. Ltd. (India) Recent Development
7.11 Bavarian Nordic (Denmark)
7.11.1 Bavarian Nordic (Denmark) Corporation Information
7.11.2 Bavarian Nordic (Denmark) Description and Business Overview
7.11.3 Bavarian Nordic (Denmark) Multivalent Vaccines Sales, Revenue and Gross Margin (2017-2022)
7.11.4 Bavarian Nordic (Denmark) Multivalent Vaccines Products Offered
7.11.5 Bavarian Nordic (Denmark) Recent Development
7.12 Mitsubishi Tanabe Pharma Corporation (Japan)
7.12.1 Mitsubishi Tanabe Pharma Corporation (Japan) Corporation Information
7.12.2 Mitsubishi Tanabe Pharma Corporation (Japan) Description and Business Overview
7.12.3 Mitsubishi Tanabe Pharma Corporation (Japan) Multivalent Vaccines Sales, Revenue and Gross Margin (2017-2022)
7.12.4 Mitsubishi Tanabe Pharma Corporation (Japan) Products Offered
7.12.5 Mitsubishi Tanabe Pharma Corporation (Japan) Recent Development
7.13 Daiichi Sankyo (Japan)
7.13.1 Daiichi Sankyo (Japan) Corporation Information
7.13.2 Daiichi Sankyo (Japan) Description and Business Overview
7.13.3 Daiichi Sankyo (Japan) Multivalent Vaccines Sales, Revenue and Gross Margin (2017-2022)
7.13.4 Daiichi Sankyo (Japan) Products Offered
7.13.5 Daiichi Sankyo (Japan) Recent Development
7.14 Protein Sciences Corporation (US)
7.14.1 Protein Sciences Corporation (US) Corporation Information
7.14.2 Protein Sciences Corporation (US) Description and Business Overview
7.14.3 Protein Sciences Corporation (US) Multivalent Vaccines Sales, Revenue and Gross Margin (2017-2022)
7.14.4 Protein Sciences Corporation (US) Products Offered
7.14.5 Protein Sciences Corporation (US) Recent Development
7.15 Panacea Biotec (India)
7.15.1 Panacea Biotec (India) Corporation Information
7.15.2 Panacea Biotec (India) Description and Business Overview
7.15.3 Panacea Biotec (India) Multivalent Vaccines Sales, Revenue and Gross Margin (2017-2022)
7.15.4 Panacea Biotec (India) Products Offered
7.15.5 Panacea Biotec (India) Recent Development
8 Industry Chain and Sales Channels Analysis
8.1 Multivalent Vaccines Industry Chain Analysis
8.2 Multivalent Vaccines Key Raw Materials
8.2.1 Key Raw Materials
8.2.2 Multivalent Vaccines Distributors
8.3 Multivalent Vaccines Production Mode & Process
8.4 Multivalent Vaccines Sales and Marketing
8.4.1 Multivalent Vaccines Sales Channels
8.4.2 Multivalent Vaccines Distributors
8.5 Multivalent Vaccines Customers
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Multivalent Vaccines CAGR in Value, United States VS Global, 2017 VS 2022 VS 2028
Table 2. Multivalent Vaccines Market Trends
Table 3. Multivalent Vaccines Market Drivers
Table 4. Multivalent Vaccines Market Challenges
Table 5. Multivalent Vaccines Market Restraints
Table 6. Global Multivalent Vaccines Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
Table 7. United States Multivalent Vaccines Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
Table 8. Global Multivalent Vaccines Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
Table 9. United States Multivalent Vaccines Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
Table 10. Top Multivalent Vaccines Manufacturers in Global Market, Ranking by Revenue (2021)
Table 11. Global Multivalent Vaccines Revenue by Manufacturer, (US$ Million), 2017-2022
Table 12. Global Multivalent Vaccines Revenue Share by Manufacturer, 2017-2022
Table 13. Global Multivalent Vaccines Sales by Manufacturer, (K Pcs), 2017-2022
Table 14. Global Multivalent Vaccines Sales Share by Manufacturer, 2017-2022
Table 15. Global Multivalent Vaccines Price by Manufacturer (2017-2022) & (USD/Pcs)
Table 16. Global Multivalent Vaccines Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 17. Global Multivalent Vaccines by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Multivalent Vaccines as of 2021)
Table 18. Top Players of Multivalent Vaccines in Global Market, Headquarters and Distribution of Producing Region
Table 19. Manufacturers Multivalent Vaccines Product Type
Table 20. Date of International Manufacturers Enter into Multivalent Vaccines Market
Table 21. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 22. Top Multivalent Vaccines Players in United States Market, Ranking by Revenue (2021)
Table 23. United States Multivalent Vaccines Revenue by Players, (US$ Million), 2020, 2021 & 2022
Table 24. United States Multivalent Vaccines Revenue Share by Players, 2020, 2021 & 2022
Table 25. United States Multivalent Vaccines Sales by Players, (K Pcs), 2020, 2021 & 2022
Table 26. United States Multivalent Vaccines Sales Share by Players, 2020, 2021 & 2022
Table 27. Global Multivalent Vaccines Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
Table 28. Global Multivalent Vaccines Sales in Volume by Region (2017-2022) & (K Pcs)
Table 29. Global Multivalent Vaccines Sales in Volume Forecast by Region (2023-2028) & (K Pcs)
Table 30. Global Multivalent Vaccines Sales in Value by Region (2017-2022) & (US$ Million)
Table 31. Global Multivalent Vaccines Sales in Value Forecast by Region (2023-2028) & (US$ Million)
Table 32. North America Multivalent Vaccines Sales in Volume by Country (2017-2028) & (K Pcs)
Table 33. North America Multivalent Vaccines Sales in Value by Country (2017-2028) & (US$ Million)
Table 34. Asia Pacific Multivalent Vaccines Sales in Volume by Region (2017-2028) & (K Pcs)
Table 35. Asia Pacific Multivalent Vaccines Sales in Value by Region (2017-2028) & (US$ Million)
Table 36. Europe Multivalent Vaccines Sales in Volume by Country (2017-2028) & (K Pcs)
Table 37. Europe Multivalent Vaccines Sales in Value by Country (2017-2028) & (US$ Million)
Table 38. Latin America Multivalent Vaccines Sales in Volume by Country (2017-2028) & (K Pcs)
Table 39. Latin Americaa Multivalent Vaccines Sales in Value by Country (2017-2028) & (US$ Million)
Table 40. Middle East and Africa Multivalent Vaccines Sales in Volume by Country (2017-2028) & (K Pcs)
Table 41. Middle East and Africa Multivalent Vaccines Sales in Value by Country (2017-2028) & (US$ Million)
Table 42. GlaxoSmithKline, plc (U.K.) Corporation Information
Table 43. GlaxoSmithKline, plc (U.K.) Description and Business Overview
Table 44. GlaxoSmithKline, plc (U.K.) Multivalent Vaccines Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 45. GlaxoSmithKline, plc (U.K.) Multivalent Vaccines Product
Table 46. GlaxoSmithKline, plc (U.K.) Recent Development
Table 47. Pfizer, Inc (US) Corporation Information
Table 48. Pfizer, Inc (US) Description and Business Overview
Table 49. Pfizer, Inc (US) Multivalent Vaccines Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 50. Pfizer, Inc (US) Product
Table 51. Pfizer, Inc (US) Recent Development
Table 52. Merck & Co., Inc (US) Corporation Information
Table 53. Merck & Co., Inc (US) Description and Business Overview
Table 54. Merck & Co., Inc (US) Multivalent Vaccines Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 55. Merck & Co., Inc (US) Product
Table 56. Merck & Co., Inc (US) Recent Development
Table 57. Sanofi Pasteur SA (France) Corporation Information
Table 58. Sanofi Pasteur SA (France) Description and Business Overview
Table 59. Sanofi Pasteur SA (France) Multivalent Vaccines Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 60. Sanofi Pasteur SA (France) Product
Table 61. Sanofi Pasteur SA (France) Recent Development
Table 62. Astellas Pharma Inc. (Japan) Corporation Information
Table 63. Astellas Pharma Inc. (Japan) Description and Business Overview
Table 64. Astellas Pharma Inc. (Japan) Multivalent Vaccines Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 65. Astellas Pharma Inc. (Japan) Product
Table 66. Astellas Pharma Inc. (Japan) Recent Development
Table 67. CSL Limited (Australia) Corporation Information
Table 68. CSL Limited (Australia) Description and Business Overview
Table 69. CSL Limited (Australia) Multivalent Vaccines Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 70. CSL Limited (Australia) Product
Table 71. CSL Limited (Australia) Recent Development
Table 72. Emergent BioSolutions, Inc (US) Corporation Information
Table 73. Emergent BioSolutions, Inc (US) Description and Business Overview
Table 74. Emergent BioSolutions, Inc (US) Multivalent Vaccines Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 75. Emergent BioSolutions, Inc (US) Product
Table 76. Emergent BioSolutions, Inc (US) Recent Development
Table 77. Johnson & Johnson (US) Corporation Information
Table 78. Johnson & Johnson (US) Description and Business Overview
Table 79. Johnson & Johnson (US) Multivalent Vaccines Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 80. Johnson & Johnson (US) Product
Table 81. Johnson & Johnson (US) Recent Development
Table 82. MedImmune, LLC (US) Corporation Information
Table 83. MedImmune, LLC (US) Description and Business Overview
Table 84. MedImmune, LLC (US) Multivalent Vaccines Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 85. MedImmune, LLC (US) Product
Table 86. MedImmune, LLC (US) Recent Development
Table 87. Serum Institute of India Pvt. Ltd. (India) Corporation Information
Table 88. Serum Institute of India Pvt. Ltd. (India) Description and Business Overview
Table 89. Serum Institute of India Pvt. Ltd. (India) Multivalent Vaccines Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 90. Serum Institute of India Pvt. Ltd. (India) Product
Table 91. Serum Institute of India Pvt. Ltd. (India) Recent Development
Table 92. Bavarian Nordic (Denmark) Corporation Information
Table 93. Bavarian Nordic (Denmark) Description and Business Overview
Table 94. Bavarian Nordic (Denmark) Multivalent Vaccines Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 95. Bavarian Nordic (Denmark) Product
Table 96. Bavarian Nordic (Denmark) Recent Development
Table 97. Mitsubishi Tanabe Pharma Corporation (Japan) Corporation Information
Table 98. Mitsubishi Tanabe Pharma Corporation (Japan) Description and Business Overview
Table 99. Mitsubishi Tanabe Pharma Corporation (Japan) Multivalent Vaccines Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 100. Mitsubishi Tanabe Pharma Corporation (Japan) Product
Table 101. Mitsubishi Tanabe Pharma Corporation (Japan) Recent Development
Table 102. Daiichi Sankyo (Japan) Corporation Information
Table 103. Daiichi Sankyo (Japan) Description and Business Overview
Table 104. Daiichi Sankyo (Japan) Multivalent Vaccines Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 105. Daiichi Sankyo (Japan) Product
Table 106. Daiichi Sankyo (Japan) Recent Development
Table 107. Protein Sciences Corporation (US) Corporation Information
Table 108. Protein Sciences Corporation (US) Description and Business Overview
Table 109. Protein Sciences Corporation (US) Multivalent Vaccines Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 110. Protein Sciences Corporation (US) Product
Table 111. Protein Sciences Corporation (US) Recent Development
Table 112. Panacea Biotec (India) Corporation Information
Table 113. Panacea Biotec (India) Description and Business Overview
Table 114. Panacea Biotec (India) Multivalent Vaccines Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 115. Panacea Biotec (India) Product
Table 116. Panacea Biotec (India) Recent Development
Table 117. Key Raw Materials Lists
Table 118. Raw Materials Key Suppliers Lists
Table 119. Multivalent Vaccines Customers List
Table 120. Multivalent Vaccines Distributors List
Table 121. Research Programs/Design for This Report
Table 122. Key Data Information from Secondary Sources
Table 123. Key Data Information from Primary Sources
List of Figures
Figure 1. Multivalent Vaccines Product Picture
Figure 2. Global Multivalent Vaccines Revenue, (US$ Million), 2017 VS 2022 VS 2028
Figure 3. Global Multivalent Vaccines Market Size 2017-2028 (US$ Million)
Figure 4. Global Multivalent Vaccines Sales 2017-2028 (K Pcs)
Figure 5. United States Multivalent Vaccines Revenue, (US$ Million), 2017 VS 2022 VS 2028
Figure 6. United States Multivalent Vaccines Market Size 2017-2028 (US$ Million)
Figure 7. United States Multivalent Vaccines Sales 2017-2028 (K Pcs)
Figure 8. United States Multivalent Vaccines Market Share in Global, in Value (US$ Million) 2017-2028
Figure 9. United States Multivalent Vaccines Market Share in Global, in Volume (K Pcs) 2017-2028
Figure 10. Multivalent Vaccines Report Years Considered
Figure 11. Product Picture of Conjugate Vaccines
Figure 12. Product Picture of Inactivated and Subunit Vaccines
Figure 13. Product Picture of Live Attenuated Vaccines
Figure 14. Product Picture of Toxoid Vaccines
Figure 15. Product Picture of Recombinant Vaccines
Figure 16. Global Multivalent Vaccines Market Share by Type in 2022 & 2028
Figure 17. Global Multivalent Vaccines Sales in Value by Type (2017-2028) & (US$ Million)
Figure 18. Global Multivalent Vaccines Sales Market Share in Value by Type (2017-2028)
Figure 19. Global Multivalent Vaccines Sales by Type (2017-2028) & (K Pcs)
Figure 20. Global Multivalent Vaccines Sales Market Share in Volume by Type (2017-2028)
Figure 21. Global Multivalent Vaccines Price by Type (2017-2028) & (USD/Pcs)
Figure 22. United States Multivalent Vaccines Market Share by Type in 2022 & 2028
Figure 23. United States Multivalent Vaccines Sales in Value by Type (2017-2028) & (US$ Million)
Figure 24. United States Multivalent Vaccines Sales Market Share in Value by Type (2017-2028)
Figure 25. United States Multivalent Vaccines Sales by Type (2017-2028) & (K Pcs)
Figure 26. United States Multivalent Vaccines Sales Market Share in Volume by Type (2017-2028)
Figure 27. United States Multivalent Vaccines Price by Type (2017-2028) & (USD/Pcs)
Figure 28. Product Picture of Pediatrics
Figure 29. Product Picture of Adults
Figure 30. Global Multivalent Vaccines Market Share by Application in 2022 & 2028
Figure 31. Global Multivalent Vaccines Sales in Value by Application (2017-2028) & (US$ Million)
Figure 32. Global Multivalent Vaccines Sales Market Share in Value by Application (2017-2028)
Figure 33. Global Multivalent Vaccines Sales by Application (2017-2028) & (K Pcs)
Figure 34. Global Multivalent Vaccines Sales Market Share in Volume by Application (2017-2028)
Figure 35. Global Multivalent Vaccines Price by Application (2017-2028) & (USD/Pcs)
Figure 36. United States Multivalent Vaccines Market Share by Application in 2022 & 2028
Figure 37. United States Multivalent Vaccines Sales in Value by Application (2017-2028) & (US$ Million)
Figure 38. United States Multivalent Vaccines Sales Market Share in Value by Application (2017-2028)
Figure 39. United States Multivalent Vaccines Sales by Application (2017-2028) & (K Pcs)
Figure 40. United States Multivalent Vaccines Sales Market Share in Volume by Application (2017-2028)
Figure 41. United States Multivalent Vaccines Price by Application (2017-2028) & (USD/Pcs)
Figure 42. North America Multivalent Vaccines Sales in Volume Growth Rate 2017-2028 (K Pcs)
Figure 43. North America Multivalent Vaccines Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 44. U.S. Multivalent Vaccines Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 45. Canada Multivalent Vaccines Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 46. Europe Multivalent Vaccines Sales in Volume Growth Rate 2017-2028 (K Pcs)
Figure 47. Europe Multivalent Vaccines Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 48. Germany Multivalent Vaccines Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 49. France Multivalent Vaccines Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 50. U.K. Multivalent Vaccines Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 51. Italy Multivalent Vaccines Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 52. Russia Multivalent Vaccines Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 53. Asia-Pacific Multivalent Vaccines Sales in Volume Growth Rate 2017-2028 (K Pcs)
Figure 54. Asia-Pacific Multivalent Vaccines Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 55. China Multivalent Vaccines Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 56. Japan Multivalent Vaccines Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 57. South Korea Multivalent Vaccines Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 58. India Multivalent Vaccines Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 59. Australia Multivalent Vaccines Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 60. Taiwan Multivalent Vaccines Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 61. Indonesia Multivalent Vaccines Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 62. Thailand Multivalent Vaccines Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 63. Malaysia Multivalent Vaccines Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 64. Philippines Multivalent Vaccines Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 65. Latin America Multivalent Vaccines Sales in Volume Growth Rate 2017-2028 (K Pcs)
Figure 66. Latin America Multivalent Vaccines Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 67. Mexico Multivalent Vaccines Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 68. Brazil Multivalent Vaccines Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 69. Argentina Multivalent Vaccines Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 70. Middle East & Africa Multivalent Vaccines Sales in Volume Growth Rate 2017-2028 (K Pcs)
Figure 71. Middle East & Africa Multivalent Vaccines Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 72. Turkey Multivalent Vaccines Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 73. Saudi Arabia Multivalent Vaccines Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 74. U.A.E Multivalent Vaccines Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 75. Multivalent Vaccines Value Chain
Figure 76. Multivalent Vaccines Production Process
Figure 77. Channels of Distribution
Figure 78. Distributors Profiles
Figure 79. Bottom-up and Top-down Approaches for This Report
Figure 80. Data Triangulation
Figure 81. Key Executives Interviewed
